What Banacep Treats: Main Uses and Benefits

Benazepril (Banacep) is commonly used for the long-term management of chronic, persistently elevated blood pressure. The primary indications for its use include managing hypertension in adults and is also considered relevant for pediatric patients, providing supportive care for heart failure, and addressing chronic kidney disease associated with hypertension.

The medication contributes to easing the symptoms related to systemic imbalance, and its use can contribute to the reduction of the patient's long-term risk of severe cardiovascular events, including stroke and myocardial infarction. In settings requiring supportive care for the heart, such as following a myocardial infarction, Benazepril is applied to provide assistance to the cardiovascular system.

Quick Fact: Therapeutic Domains

Regulatory References

1. DailyMed/NIH Label Information

Who Can and Cannot Use Banacep?

The eligibility for using Banacep (Benazepril) is strictly defined by regulatory authorities and centers on specific patient conditions and demographic factors.

Absolute Contraindications (Must Not Use)

Banacep is contraindicated and must not be used by patients with a history of angioedema, whether hereditary, idiopathic, or related to previous treatment with any Angiotensin-Converting Enzyme (ACE) inhibitor. Use is also prohibited for patients with known hypersensitivity to Benazepril or other ACE inhibitors. It is absolutely contraindicated during the second and third trimesters of pregnancy.

Furthermore, it must not be used concomitantly with Aliskiren in patients with Diabetes Mellitus, or with a Neprilysin Inhibitor (e.g., Sacubitril/Valsartan).

Age and Conditional Restrictions

Use is approved for adults and pediatric patients 6 years of age and older for hypertension. It is not recommended for children under 6 years as safety is not established. Treatment must be discontinued immediately if pregnancy is detected, and use during the first trimester and while breastfeeding (especially newborns) is not recommended. Patients with severe renal impairment (Glomerular Filtration Rate leq 30 mL/min/1.73 m^2) require specific caution and may necessitate a reduced initial dose.

Official Regulatory Interaction Profile

Formal Contraindications and Restrictions Co-administration with neprilysin inhibitors (e.g., sacubitril/valsartan) is explicitly contraindicated due to the high risk of angioedema. A mandatory 36-hour separation period must be observed when switching between these agents. Furthermore, the combination with aliskiren is contraindicated in all patients with diabetes due to increased risks of hyperkalemia, renal impairment, and hypotension.

Pharmacodynamic Interactions and Exposure Modification Interactions affecting key physiological parameters are documented. Combining Benazepril with potassium-sparing diuretics or potassium supplements/salt substitutes may lead to an additive effect, increasing the risk of hyperkalemia. Co-administration with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may result in the loss of the antihypertensive effect and increases the risk of renal dysfunction; this risk is specifically noted as heightened in elderly or volume-depleted patients. Exposure modification is documented with Lithium, which may experience an increase in serum concentration due to reduced renal clearance. The co-administration of mTOR inhibitors (e.g., sirolimus) also increases the risk of angioedema.

Drug-Substance Interactions Alcohol may contribute to additive effects in lowering blood pressure.

Banacep functions as a selective inhibitor of the c-Src tyrosine kinase pathway within osteoclasts. This inhibition disrupts the c-Src-dependent phosphorylation cascade necessary for the activation and assembly of the ruffled border, which is the specialized organelle responsible for acid secretion and enzyme release. Concurrently, Banacep modulates the expression of TRAP (tartrate-resistant acid phosphatase) and cathepsin K. This action regulates the degradation of the mineralized bone matrix and modifies the lifespan of the osteoclast cell population. The compound alters signaling within the bone remodeling unit and modulates the rate of bone resorption relative to bone formation, affecting overall bone turnover. This systemic impact on osteoclast function, which impacts the structural organization of bone tissue, results in a net decrease in the release of certain catabolic cytokines.

Banacep (Benazepril) is administered orally and is primarily available as a tablet in multiple strengths, including 5 mg, 10 mg, 20 mg, and 40 mg. The medication can be taken with or without food, as its absorption is not significantly affected by meals.

Therapy for adults with hypertension is typically initiated at a starting dose of 10 mg once daily when the patient is not currently receiving a diuretic. A lower initial dose of 5 mg once daily is specified for individuals concurrently taking a diuretic, and the diuretic should ideally be discontinued prior to starting Banacep. The standard adult maintenance dosage range generally falls between 20 mg and 40 mg per day. While the usual frequency is once daily, the total daily amount may be given in two equally divided doses (twice daily).

Specific procedural rules govern administration for certain patient populations. For adults with severe renal impairment (glomerular filtration rate ≤ 30 mL/min/1.73 m^2), the required initial dose is reduced to 5 mg once daily, with a maximum daily dose of 40 mg. For pediatric patients six years of age and older, the labeled treatment begins with a weight-based dose of 0.2 mg/kg once daily. Furthermore, an oral suspension can be extemporaneously compounded for patients who cannot swallow tablets; this preparation must be refrigerated and shaken before use.

Research evidence / Overview of studies for Banacep

Evidence for Use in Managing Chronic High Blood Pressure (Hypertension)

The research for Benazepril was conducted in the context of persistently high blood pressure (hypertension) and involves long-term randomized controlled trials (RCTs) and other studies. These studies explored the use of Benazepril in adults with high blood pressure, including those who may also have other cardiovascular risk factors or existing conditions. Researchers examined whether Benazepril was associated with changes in blood pressure measurements and monitored long-term outcomes, such as the incidence of major cardiovascular events. Large-scale research projects were conducted to observe patterns in outcomes related to major cardiovascular events, such as nonfatal stroke or myocardial infarction.

However, a key limitation documented in the scientific literature is that the most substantial long-term evidence related to the incidence of major cardiovascular events often comes from studies where Benazepril was used in combination with other classes of antihypertensive medications.

Evidence for Use in Managing Progressive Kidney Disease

Benazepril was studied for its use in conditions associated with functional limitations and chronic systemic imbalance, specifically in adults with non-diabetic chronic kidney disease (CKD). These intermediate- and long-term randomized trials evaluated changes in urinary protein excretion (proteinuria) and observed patterns related to composite renal endpoints over several years. Trials reported patterns associated with the doubling of serum creatinine, the need for dialysis, or death in the observed treatment groups compared to placebo groups.

Research is ongoing, and the certainty remains low regarding the full picture for patients with diabetic kidney disease, as existing evidence is predominantly derived from non-diabetic populations.

Evidence in Special Populations

Specific research exploring short-term changes has been conducted on the use of Benazepril in special populations, particularly children aged 6 to 16 years with elevated blood pressure. Studies explored blood pressure measurements and were designed to evaluate the dose-response relationship in this younger group. Evidence for use remains uncertain for children younger than 6 or those with severe renal impairment, as these groups were typically excluded from the main trials. Long-term effects are not fully established for children, as the research primarily focuses on short-term blood pressure measures.

Key Studies & References

1. Benazepril Hydrochloride Tablet, DailyMed Label Information (Regulatory Summary)

Common questions about Banacep (FAQ)

Q: What is Banacep used for?

A: Banacep is a prescription medication indicated for the management of mild to moderate essential hypertension (high blood pressure) and as adjunctive therapy in managing chronic heart failure. Its use in these conditions has been studied in clinical trials.

Q: How does Banacep work in the body?

A: Banacep is classified as an ACE (Angiotensin-Converting Enzyme) inhibitor. This class of medication works to interrupt a specific biochemical process in the body, which can lead to vasodilation (widening of blood vessels) and reduced fluid retention.

Q: What are the common observations of taking Banacep?

A: Clinical trial data suggests that the most frequently reported observations in participants receiving Banacep included a persistent, dry cough, dizziness, and fatigue. Headaches were also commonly noted. Individuals who experience these or other effects should consult their healthcare provider for evaluation.

Q: Is Banacep effective for lowering blood pressure?

A: Research studies have observed that individuals with hypertension who were given Banacep generally experienced a measurable reduction in systolic and diastolic blood pressure readings compared to baseline measurements. The extent of this effect may vary among individuals.

Q: Can I stop taking Banacep once my blood pressure is normal?

A: Changes to any prescribed medication regimen, including the decision to discontinue a medication, should only be made under the direct supervision and guidance of a qualified healthcare professional. Consistent use, as determined by the prescriber, is typically important for chronic conditions.

How to Store and Dispose of Banacep?

Benazepril tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture, requiring the container to be kept tightly closed to prevent degradation. It is mandatory to keep the product out of the sight and reach of children.

Storage Summary

Compounded oral suspensions of Benazepril must be stored under refrigeration (2 C to 8 C) and discarded after 30 days. Unused or expired Benazepril must be disposed of in accordance with local requirements and should not be discarded via wastewater or household waste.